[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Valued at $7.88 billion, Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company. Its proprietary technology platform focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. 

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction, a Weighted Alpha above 50+, and a 60-month beta above 1.5. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. PTGX checks those boxes. The Trend Seeker issued a new “Buy” signal on June...

Fundamentals

See More
  • Market Capitalization, $K 8,464,612
  • Shares Outstanding, K 64,311
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ -142 M
  • EBITDA $ -147 M
  • 60-Month Beta 1.79
  • Price/Sales 174.93
  • Price/Cash Flow N/A
  • Price/Book 12.91

Options Overview Details

View History
  • Implied Volatility 65.81% (+1.63%)
  • Historical Volatility 45.60%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 65.81% on 07/02/26
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 12) 5.53 (4.20%)
  • Put/Call Vol Ratio 0.65
  • Today's Volume 51
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 7,489
  • Open Int (30-Day) 8,411
  • Expected Range 126.10 to 137.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.11
  • Number of Estimates 3
  • High Estimate $2.54
  • Low Estimate $1.61
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) +483.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.00 +41.53%
on 06/03/26
131.87 -0.19%
on 07/02/26
+38.39 (+41.18%)
since 06/02/26
3-Month
92.75 +41.91%
on 06/02/26
131.87 -0.19%
on 07/02/26
+27.84 (+26.83%)
since 04/02/26
52-Week
49.38 +166.55%
on 07/08/25
131.87 -0.19%
on 07/02/26
+80.93 (+159.66%)
since 07/02/25

Most Recent Stories

More News
Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (PTGX) exhibits strong technical momentum, posting a 150% gain over the past 52 weeks. PTGX holds a 100% “Buy” technical opinion from Barchart. Despite bullish analyst sentiment...

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance...

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

NEWARK, CA / ACCESS Newswire / June 1, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that four abstracts highlighting rusfertide in polycythemia vera (PV) will...

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

NEWARK, CA / ACCESS Newswire / May 28, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer,...

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 131.62 (+5.15%)
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible...

PTGX : 131.62 (+5.15%)
PTGX: The Partnership Everyone's Celebrating Might Be the Problem

Barchart Research What to Expect from PTGX Earnings PTGX Generated May 4, 2026 Current Price $99.52 EPS Estimate $$-0.65 Consensus Rating Strong Buy Average Move 3.25% PTGX: The Partnership Everyone's...

PTGX : 131.62 (+5.15%)
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera

PTGX : 131.62 (+5.15%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance...

PTGX : 131.62 (+5.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 140.54
2nd Resistance Point 136.21
1st Resistance Point 133.91
Last Price 131.62
1st Support Level 127.28
2nd Support Level 122.95
3rd Support Level 120.65

See More

52-Week High 131.87
Last Price 131.62
Fibonacci 61.8% 100.36
Fibonacci 50% 90.63
Fibonacci 38.2% 80.89
52-Week Low 49.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.